The Swissmedic (Swiss Medicines and Medical Devices Authority) has received an application for the registration of a coronavirus vaccine developed by the German company CureVac. This is reported by Deutsche welle.
CureVac expects its CVnCoV vaccine to be registered in the EU this quarter.
This will be the third coronavirus vaccine based on innovative mRNA technology. BioNTech / Pfizer and Moderna vaccines were created using the same technology.
The Swiss federal government is known to have signed a contract with CureVac to supply 5 million doses of the vaccine.
Vaccines from BioNTech / Pfizer, Moderna and Johnson & Johnson are currently approved in Switzerland.
In January this year, the German biotechnology company CureVac and the pharmaceutical concern Bayer entered into a cooperation agreement with the aim of mass production and global distribution of the coronavirus vaccine.
Special hopes are pinned on this vaccine in Germany and throughout the European Union. In November 2020, the EU ordered 405 million doses from CureVac. In addition, in the spring of 2020, Brussels provided the company with a loan of 80 million euros, and the German government even invested capital in it, buying shares for 300 million euros.